Abstract
Neurolymphomatosis (NL) is a rare condition involving the infiltration of lymphoma cells into the peripheral nervous system. NL can be primary or secondary in the setting of an unknown or known hematologic malignancy, respectively. Here, we report five cases in which F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (F-18 FDG-PET/CT) had great value for diagnosing NL. Two cases were rare primary NL, and the other three were secondary NL. Clinical presentations were asymmetric sensorimotor disturbances in the extremities with or without involvement of cranial nerves. Furthermore, all patients experienced spontaneous pain in the face or affected extremities. Cerebrospinal fluid analysis was cytologically negative in two of five cases. Gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) detected abnormalities in the cranial nerves, nerve roots, and cauda equina in all cases except case 1 and the recurrent stage of case 2. F-18 FDG-PET/CT showed clear visualization of almost all the lymphomatous involvement of peripheral nerves and other tissues in all patients. Furthermore, F-18 FDG-PET/CT detected abnormalities including asymptomatic lesions that were not detected with MRI, and also identified the appropriate lesion for diagnostic biopsy. However, as in case 3, the lesions in the left oculomotor nerve and the cauda equina were detected only with Gd-enhanced MRI, which has superior spatial resolution. In conclusion, F-18 FDG-PET/CT is a sensitive modality that can suggest the presence of malignancy and identify appropriate places for diagnostic biopsies. It is especially useful when combined with Gd-enhanced MRI, even in patients with primary NL that is usually difficult to diagnose.
This is a preview of subscription content, log in via an institution to check access.
References
Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, Kuittinen O, Chamberlain MC, Roth P, Nemets A, Shalom E, Ben-Yehuda D, Siegal T, International Primary CNS Lymphoma Collaborative Group (2010) Neurolymphomatosis: an international primary CNS lymphoma collaborative group report. Blood 115:5005–5011
Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH (2003) Neurolymphomatosis. Neuro Oncol 5:104–115
van den Bent MJ, de Bruin HG, Bos GM, Brutel de la Rivière G, Sillevis Smitt PA (1999) Negative sural nerve biopsy in neurolymphomatosis. J Neurol 246:1159–1163
Tomita M, Koike H, Kawagashira Y, Iijima M, Adachi H, Taguchi J, Abe T, Sako K, Tsuji Y, Nakagawa M, Kanda F, Takeda F, Sugawara M, Toyoshima I, Asano N, Sobue G (2013) Clinicopathological features of neuropathy associated with lymphoma. Brain 136:2563–2578
Nakajima S, Okada T, Yamamoto A, Kanagaki M, Fushimi Y, Okada T, Arakawa Y, Takagi Y, Miyamoto S, Togashi K (2015) Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography. Clin Imaging 39:390–395
Salm LP, Van der Hiel B, Stokkel MP (2012) Increasing importance of 18F-FDG PET in the diagnosis of neurolymphomatosis. Nucl Med Commun 33:907–916
Hong RS, Woodson EA, Hansen MR (2009) Neurolymphomatosis mimicking chemotherapy-induced ototoxicity. Otol Neurotol 30:566–569
Santos E, Scolding NJ (2010) Neurolymphomatosis mimicking neurosarcoidosis: a case report. J Med Case Rep 4:5
Shaikh F, Chan AC, Awan O, Jerath N, Reddy C, Khan SA, Graham MM (2015) Diagnostic yield of FDG-PET/CT, MRI, and CSF cytology in non-biopsiable neurolymphomatosis as a heralding sign of recurrent non-Hodgkin’s lymphoma. Cureus 7:e319
Lahoria R, Dyck PJ, Macon WR, Crum BA, Spinner RJ, Amrami KK, Zeldenrust SR, Tracy JA (2015) Neurolymphomatosis: a report of 2 cases representing opposite ends of the clinical spectrum. Muscle Nerve 52:449–454
Ropper AH, Samuels MA (2009) Diseases of the peripheral nerves. In: Ropper AH, Samuels MA (eds) Adams and Victor’s principles of neurology, 9th edn. McGraw-Hill Companies, New York, pp 1280–1287
Saperstein DS, Amato AA, Wolfe GI, Katz JS, Nations SP, Jackson CE, Bryan WW, Burns DK, Barohn RJ (1999) Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 22:560–566
Bartels S, Kyavar L, Blumstein N, Görg T, Glöckner SC, Zimmermann R, Heckmann JG (2013) FDG PET findings leading to diagnosis of neurosarcoidosis. Clin Neurol Neurosurg 115:85–88
Glaudemans AW, Slart RH, Noordzij W, Dierckx RA, Hazenberg BP (2013) Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis. Eur J Nucl Med Mol Imaging 40:1095–1101
Broski SM, Spinner RJ, Howe BM, Dispenzieri A, Johnson GB (2016) 18F-florbetapir and 18F-FDG PET/CT in systemic immunoglobulin light chain amyloidosis involving the peripheral nerves. Clin Nucl Med 41:e115–e117
Cheson BD (2011) Role of functional imaging in the management of lymphoma. J Clin Oncol 29:1844–1854
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflicts of interest
On behalf of all authors, the corresponding authors state that there is no conflict of interest.
Ethical standard
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee Graduate School and Faculty of Medicine Kyoto University, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual patients or the family members of the deceased.
Rights and permissions
About this article
Cite this article
Kinoshita, H., Yamakado, H., Kitano, T. et al. Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases. J Neurol 263, 1719–1726 (2016). https://doi.org/10.1007/s00415-016-8190-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-016-8190-4